GlassScriptPhysician profile
Charles J Winters
NPI 1275578205
$2,849.67
in general payments reported to CMS, 2019-2025
31 companies · $164 in 2025
The $164 reported for 2025 was less than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,354 · 2020: $440 · 2021: $204 · 2022: $243 · 2023: $305 · 2024: $140 · 2025: $164.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $609.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $608.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $1,001.60 | 2019 | |
| Abbott Laboratories | $444.49 | 2019-2025 | Proclaim, Eterna, Octrode |
| Si-Bone, INC. | $187.00 | 2020-2025 | |
| Medtronic, INC. | $167.21 | 2023-2025 | Inceptiv, Intellis Adaptivestim, Crescent Spinal System |
| Medacta USA, INC. | $111.77 | 2024-2025 | Nextar Spine Platform |
| Providence Medical Technology, INC. | $106.64 | 2021-2022 | |
| Boston Scientific Corporation | $105.42 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $91.05 | 2020-2021 | |
| Xtant Medical INC | $76.64 | 2023 | |
| Stryker Corporation | $61.70 | 2021 | |
| Surgalign Spine Technologies, INC. | $46.06 | 2019 | |
| Cerapedics INC. | $45.17 | 2023 | I-Factor Peptide Enhanced Bone Graft |
| Saluda Medical Americas, INC. | $38.85 | 2024 | Evoke |
| Ge Healthcare | $35.19 | 2019 | |
| Ucb, INC. | $32.64 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $31.17 | 2019-2021 | |
| Nevro Corp. | $30.30 | 2019 | |
| Tersera Therapeutics LLC | $30.14 | 2019 | |
| Integra Lifesciences Corporation | $27.35 | 2019 | |
| Molnlycke Health Care US, LLC | $22.47 | 2023 | Mepilex Border Post-Op Ag |
| Pacira Therapeutics, INC. | $17.55 | 2020 | |
| Upsher-Smith Laboratories LLC | $17.36 | 2020 | |
| Scilex Pharmaceuticals INC. | $16.23 | 2020 | |
| Daiichi Sankyo INC. | $14.48 | 2019 | |
| Elevation Spine, INC. | $14.26 | 2024 | |
| Flowonix Medical Incorporated | $13.69 | 2019 | |
| Biogen, INC. | $13.19 | 2019 | |
| Lilly USA, LLC | $13.01 | 2019 | |
| Csl Behring | $12.95 | 2020 | |
| Stimwave Technologies Incorporated | $12.92 | 2020 | |
| Akcea Therapeutics, INC. | $11.17 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Winters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.